Moreover, NRF2 activation may be beneficial not only in reducing adverse effects but also in enhancing cancer immunotherapy via inhibiting the immunosuppressive and tumor-promoting functions of myeloid-derived suppressor cells (MDSCs) [40,41]. The gene discussed is NFE2L2; the disease is cancer.